Fig. 1

Distribution of diagnosis by site groups and across all years, from 2016 to 2022 (n = 547). Notes Site groups with no available percentage data in the figure reported less than 2% of total cases for the respective year. The exact value was not included because of space limitations. Group I: Leukemias, myeloproliferative diseases, myelodysplastic diseases; Group II: Lymphomas and reticuloendothelial neoplasms; Group III: CNS and miscellaneous intracranial and intraspinal neoplasms; Group IV: Neuroblastoma and other peripheral nervous cell tumors; Group V: Retinoblastoma; Group VI: Renal tumors; Group VII: Hepatic tumors; Group VIII: Malignant bone tumors, Group IX: Soft tissue and other extraosseous sarcomas; Group X: Germ cell tumors, trophoblastic tumors, and neoplasms of gonads; Group XI: Other malignant epithelial neoplasms and malignant melanomas; Group XII: Other and unspecified malignant neoplasms